<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34884276</PMID><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>23</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>26</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Long COVID in Inflammatory Bowel Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5575</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm10235575</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">SARS-CoV-2-infected patients can experience long-lasting symptoms even after the resolution of the acute infection. This condition, defined as Long COVID, is now recognized as a public health priority and its negative impact on the quality of life of the patients could be more relevant in individuals with debilitating pathologies. We here evaluated the frequency of Long COVID in patients with inflammatory bowel diseases (IBD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">IBD patients afferent for scheduled visits to our tertiary referral center at the Tor Vergata University Hospital, Rome, were recruited from 7 September to 22 October 2021. During the visits, patients were investigated about previous COVID-19 infection and the possible development of Long COVID.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-three out of 528 IBD patients (10%) have had a SARS-CoV-2 infection. Of these, 21 patients (40%) developed Long COVID, and asthenia was the more frequent symptom as it occurred in nearly two-thirds of patients. Patients with Long COVID were more frequently females, while other clinical and demographic characteristics did not differ between patients with Long COVID and those without Long COVID. In particular, the IBD relapses occurred with the same frequency in the two groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Long COVID appears to be common in IBD patients even though it does not influence the IBD course.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salvatori</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4980-6289</Identifier><AffiliationInfo><Affiliation>Gastroenterology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldassarre</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mossa</LastName><ForeName>Michelangela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gastroenterology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monteleone</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Gastroenterology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">biologics</Keyword><Keyword MajorTopicYN="N">ulcerative colitis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34884276</ArticleId><ArticleId IdType="pmc">PMC8658587</ArticleId><ArticleId IdType="doi">10.3390/jcm10235575</ArticleId><ArticleId IdType="pii">jcm10235575</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rader B., Scarpino S.V., Nande A., Hill A.L., Adlam B., Reiner R.C., Pigott D.M., Gutierrez B., Zarebski A.E., Shrestha M., et al. Crowding and the shape of COVID-19 epidemics. Nat. Med. 2020;26:1829&#x2013;1834. doi: 10.1038/s41591-020-1104-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1104-0</ArticleId><ArticleId IdType="pubmed">33020651</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fusco M., Shea K.M., Lin J., Nguyen J.L., Angulo F.J., Benigno M., Malhotra D., Emir B., Sung A.H., Hammond J.L., et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. J. Med. Econ. 2021;24:308&#x2013;317. doi: 10.1080/13696998.2021.1886109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13696998.2021.1886109</ArticleId><ArticleId IdType="pubmed">33555956</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141&#x2013;154. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., Liu L., Shan H., Lei C.-L., Hui D.S.C., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708&#x2013;1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Casas-Rojo J., Ant&#xf3;n-Santos J., Mill&#xe1;n-N&#xfa;&#xf1;ez-Cort&#xe9;s J., Lumbreras-Bermejo C., Ramos-Rinc&#xf3;n J., Roy-Vallejo E., Artero-Mora A., Arnalich-Fern&#xe1;ndez F., Garc&#xed;a-Bru&#xf1;&#xe9;n J., Vargas-N&#xfa;&#xf1;ez J., et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry. Rev. Cl&#xed;n. Esp. 2020;220:480&#x2013;494. doi: 10.1016/j.rce.2020.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rce.2020.07.003</ArticleId><ArticleId IdType="pmc">PMC7368900</ArticleId><ArticleId IdType="pubmed">33994573</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Liao Y.S., Gong J., Liu J., Xia X., Zhang H. Clinical characteristics of coronavirus disease (COVID-19) patients with gastrointestinal symptoms: A report of 164 cases. Dig. Liver Dis. 2020;52:1076&#x2013;1079. doi: 10.1016/j.dld.2020.04.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2020.04.034</ArticleId><ArticleId IdType="pmc">PMC7205655</ArticleId><ArticleId IdType="pubmed">32507692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I., Timens W., Bulthuis M.L.C., Lely A.T., Navis G.J., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203:631&#x2013;637. doi: 10.1002/path.1570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E., Janvier P., Kherabi Y., le Bot A., Hamon A., Gouze H., Doucet L., Berkani S., Oliosi E., Mallart E., et al. Postdischarge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect. 2020;81:e4&#x2013;e6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid&#x2014;Mechanisms, risk factors, and management. BMJ. 2021;374:1&#x2013;18. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Macdonald T.T., Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920&#x2013;1925. doi: 10.1126/science.1106442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1106442</ArticleId><ArticleId IdType="pubmed">15790845</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteleone G., Pallone F., MacDonald T.T. Emerging immunological targets in inflammatory bowel disease. Curr. Opin. Pharmacol. 2011;11:640&#x2013;645. doi: 10.1016/j.coph.2011.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2011.09.013</ArticleId><ArticleId IdType="pubmed">22000933</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulai P.S., Thompson K.D., Blunt H.B., Dubinsky M.C., Siegel C.A. Risks of serious infection or lymphoma with anti-tumor necrosisfactor therapy for pediatric inflammatory bowel disease: A systematic review. Clin. Gastroenterol. Hepatol. 2014;12:1443&#x2013;1451. doi: 10.1016/j.cgh.2014.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2014.01.021</ArticleId><ArticleId IdType="pubmed">24462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi K., Singh Y., Sauk J., Parian A., Limketkai B. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Inflamm. Bowel Dis. 2021;20:1&#x2013;15. doi: 10.1093/ibd/izab236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izab236</ArticleId><ArticleId IdType="pmc">PMC8574492</ArticleId><ArticleId IdType="pubmed">34718595</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles S.R., Graff L., Wilding H., Hewitt C., Keefer L., Mikocka-Walus A. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses&#x2014;Part I. Inflamm. Bowel Dis. 2018;24:742&#x2013;751. doi: 10.1093/ibd/izx100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izx100</ArticleId><ArticleId IdType="pubmed">29562277</ArticleId></ArticleIdList></Reference><Reference><Citation>Marafini I., Longo L., Lavasani D.M., Rossi R., Salvatori S., Pianigiani F., Calabrese E., Siracusano A., Di Lorenzo G., Monteleone G. High Frequency of Undiagnosed Psychiatric Disorders in Inflammatory Bowel Diseases. J. Clin. Med. 2020;9:1387. doi: 10.3390/jcm9051387.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9051387</ArticleId><ArticleId IdType="pmc">PMC7291309</ArticleId><ArticleId IdType="pubmed">32397198</ArticleId></ArticleIdList></Reference><Reference><Citation>Marafini I., Salvatori S., Sena G., Calabrese E., Biancone L., Monteleone G. Low frequency of COVID-19 in inflammatory bowel diseases. Dig. Liver Dis. 2020;52:1234&#x2013;1235. doi: 10.1016/j.dld.2020.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2020.06.007</ArticleId><ArticleId IdType="pmc">PMC7293454</ArticleId><ArticleId IdType="pubmed">32601036</ArticleId></ArticleIdList></Reference><Reference><Citation>Scucchi L., Neri B., Sarmati L., Mossa M., Sena G., Massoud R., Petruzziello C., Musumeci M., Marafini I., Calabrese E., et al. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 2021;25:2418&#x2013;2424.</Citation><ArticleIdList><ArticleId IdType="pubmed">33755981</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ani A.H., Prentice R.E., Rentsch C.A., Johnson D., Ardalan Z., Heerasing N., Garg M., Campbell S., Sasadeusz J., Macrae F.A., et al. Review article: Prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment. Pharmacol. Ther. 2020;52:54&#x2013;72. doi: 10.1111/apt.15779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15779</ArticleId><ArticleId IdType="pmc">PMC7267115</ArticleId><ArticleId IdType="pubmed">32348598</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteleone G., Ardizzone S. Are patients with inflammatory bowel disease at increased risk for covid-19 infection? J. Crohn&#x2019;s Colitis. 2020;14:1334&#x2013;1336. doi: 10.1093/ecco-jcc/jjaa061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjaa061</ArticleId><ArticleId IdType="pmc">PMC7184365</ArticleId><ArticleId IdType="pubmed">32215548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>